Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 46,264 Janux Therapeutics, Inc. (NASDAQ:JANX)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 46,264 shares of the company's stock, valued at approximately $2,477,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.09% of Janux Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Janux Therapeutics during the 4th quarter worth $59,000. Meeder Asset Management Inc. purchased a new position in shares of Janux Therapeutics during the 4th quarter worth approximately $159,000. Tower Research Capital LLC TRC raised its holdings in shares of Janux Therapeutics by 878.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock worth $205,000 after acquiring an additional 3,436 shares during the last quarter. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth about $221,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JANX has been the topic of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. Scotiabank reduced their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Finally, Wedbush reaffirmed an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Janux Therapeutics presently has an average rating of "Buy" and an average price target of $95.25.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. acquired 110,206 shares of Janux Therapeutics stock in a transaction dated Friday, March 7th. The shares were bought at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This trade represents a 1.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 8.10% of the company's stock.

Janux Therapeutics Stock Down 1.2%

JANX traded down $0.30 during trading on Wednesday, hitting $25.13. The company had a trading volume of 543,953 shares, compared to its average volume of 876,907. The company has a market capitalization of $1.49 billion, a PE ratio of -21.48 and a beta of 3.24. The firm's 50-day moving average price is $27.18 and its 200 day moving average price is $38.24. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.